82 medicines have been added to the list of medicines that cannot be parallel exported from the UK

By | Other | No Comments

List of medicines that cannot be parallel exported from the UK

Updated 

Name Strength Pharmaceutical form Date of restriction
Accusol 35 all all 21/03/2020 00:00
Adrenaline all all 04/10/2019 00:00
Albumin all all 21/03/2020 00:00
Alfentanil all all 21/03/2020 00:00
Alprostadil all all 18/10/2019 00:00
Amikacin all all 21/03/2020 00:00
Amiodarone all all 21/03/2020 00:00
Amoxicillin all all 21/03/2020 00:00
Anidulafungin all all 21/03/2020 00:00
Argipressin all all 21/03/2020 00:00
Atracurium all all 21/03/2020 00:00
Azathioprine all tablets 26/02/2020 00:00
Calcium all all 21/03/2020 00:00
Caspofungin all all 21/03/2020 00:00
Ceftazidime all all 21/03/2020 00:00
Ceftriaxone all all 21/03/2020 00:00
Cefuroxime all all 21/03/2020 00:00
Chloroquine phosphate all all 26/02/2020 00:00
Cisatracurium all all 21/03/2020 00:00
Clarithromycin all all 21/03/2020 00:00
Clonidine all all 21/03/2020 00:00
Co-amoxiclav all all 21/03/2020 00:00
Colestyramine all oral powder sachets, oral powder sachets sugar free 05/12/2019 00:00
Conjugated oestrogens all all 04/10/2019 00:00
Conjugated oestrogens + Bazedoxifene all all 04/10/2019 00:00
Conjugated oestrogens + Medroxyprogesterone all all 04/10/2019 00:00
Cyclizine all all 21/03/2020 00:00
Dalteparin all all 21/03/2020 00:00
Dexmedetomidine all all 21/03/2020 00:00
Dobutamine all all 21/03/2020 00:00
Enoxaparin all all 21/03/2020 00:00
Epoprostenol all all 21/03/2020 00:00
Erythromycin all all 21/03/2020 00:00
Esmolol all all 21/03/2020 00:00
Esomeprazole all all 21/03/2020 00:00
Estradiol all all 04/10/2019 00:00
Estradiol + Dydrogesterone all all 04/10/2019 00:00
Estradiol + Levonorgestrel all all 04/10/2019 00:00
Estradiol + Medroxyprogesterone all all 04/10/2019 00:00
Estradiol + Norethisterone acetate all all 04/10/2019 00:00
Estradiol + Norgestrel all all 04/10/2019 00:00
Estriol all all 04/10/2019 00:00
Fentanyl all all 21/03/2020 00:00
Flucloxacillin all all 21/03/2020 00:00
Fluticasone all nasal drops 05/12/2019 00:00
Furosemide all all 21/03/2020 00:00
Gentamicin all all 21/03/2020 00:00
Glyceryl trinitrate all all 21/03/2020 00:00
Granisetron all all 21/03/2020 00:00
Hemolactol all all 21/03/2020 00:00
Hemosol B0 all all 21/03/2020 00:00
Heparin sodium all all 21/03/2020 00:00
Hepatitis A + B vaccine all all 14/11/2019 00:00
Hepatitis B vaccine all all 04/10/2019 00:00
Hydrocortisone all all 21/03/2020 00:00
Hydroxychloroquine all all 14/03/2020 00:00
Insulin all all 21/03/2020 00:00
Ketamine all all 21/03/2020 00:00
Lactasol all all 21/03/2020 00:00
Lansoprazole all all 21/03/2020 00:00
Levofloxacin all all 21/03/2020 00:00
Levonorgestrel all all 04/10/2019 00:00
Linezolid all all 21/03/2020 00:00
Lopinavir + Ritonavir all all 26/02/2020 00:00
Lorazepam all all 21/03/2020 00:00
Magnesium all all 21/03/2020 00:00
Measles + Mumps + Rubella vaccine all all 06/11/2019 00:00
Medroxyprogesterone all all 04/10/2019 00:00
Meropenem all all 21/03/2020 00:00
Metoclopramide all all 21/03/2020 00:00
Micafungin all all 21/03/2020 00:00
Midazolam all all 21/03/2020 00:00
Milrinone all all 21/03/2020 00:00
Misoprostol all tablets 06/11/2019 00:00
Monosul all all 21/03/2020 00:00
Morphine all all 21/03/2020 00:00
Morphine sulfate all all 21/03/2020 00:00
Noradrenaline all all 21/03/2020 00:00
Norethisterone all all 18/10/2019 00:00
Omeprazole all all 21/03/2020 00:00
Ondansetron all all 21/03/2020 00:00
Ondansetron all all 21/03/2020 00:00
Oseltamivir all all 04/10/2019 00:00
Ospemifene all all 04/10/2019 00:00
Oxycodone all all 21/03/2020 00:00
Pantoprazole all all 21/03/2020 00:00
Paracetamol all all 21/03/2020 00:00
Piperacillin all all 21/03/2020 00:00
Plasma-Lyte all all 21/03/2020 00:00
Pneumococcal vaccine all all 06/11/2019 00:00
Potassium chloride all all 21/03/2020 00:00
Potassium chloride all all 21/03/2020 00:00
Prazosin all tablets 04/10/2019 00:00
Prednisolone all all 21/03/2020 00:00
Prismasol 4 all all 21/03/2020 00:00
PrismOcal B22 all all 21/03/2020 00:00
Prismocitrate 18/0 all all 21/03/2020 00:00
Progesterone all all 04/10/2019 00:00
Propofol all all 21/03/2020 00:00
QVAR all inhaler 18/10/2019 00:00
Ranitidine all all 18/10/2019 00:00
Remifentanil all all 21/03/2020 00:00
Rifampicin all all 21/03/2020 00:00
Rivaroxaban all tablets 04/10/2019 00:00
Rocuronium all all 21/03/2020 00:00
Sodium chloride all all 21/03/2020 00:00
Sodium dihydrogen phosphate all all 21/03/2020 00:00
Sodium lactate all all 21/03/2020 00:00
Suxamethonium all all 21/03/2020 00:00
Teicoplanin all all 21/03/2020 00:00
Terlipressin all all 21/03/2020 00:00
Tibolone all all 04/10/2019 00:00
Tinzaparin all all 21/03/2020 00:00
Vancomycin all all 21/03/2020 00:00
Voriconazole all all 21/03/2020 00:00

Class 2 Medicines Recall: Esmya 5mg tablets

By | News, UK Pharma | No Comments

Gedeon Richter (UK) Ltd is recalling all unexpired stock of the above products from patients, pharmacies and wholesalers following a new case of liver failure requiring liver transplant in a patient taking the medicine. To protect patients while a safety review is conducted, the European Medicines Agency’s safety committee, Pharmacovigilance Risk Assessment Committee, (PRAC) has recommended that women stop taking 5mg ulipristal acetate (Esmya and generic medicines) for uterine fibroids.

Note: This recall does not affect the 30mg single dose ulipristal acetate emergency contraceptive products.

Advice for healthcare professionals

  • Contact patients who have been supplied Esmya and ask them to stop taking their medication as soon as possible and return any unused medicine to their pharmacy. All patients currently being treated with Esmya/ulipristal acetate for uterine fibroids should contact their doctor for advice about other possible treatments for uterine fibroids.
  • Stop supplying the above products immediately and remove from the shelves within your store. Quarantine all remaining stock and return it to your supplier using your supplier’s approved process.
  • Stop prescribing Esmya or generic ulipristal acetate for the treatment of uterine fibroids. No new patients should start treatment with the medicines, which has been suspended throughout the EU during the review. Consider other treatment options as appropriate.
  • Liver function testing should be performed 2- 4 weeks after treatment has stopped as described in the product information for the medicines.
  • Healthcare professionals should alert patients to immediately report signs and symptoms of liver injury (such as nausea, vomiting, right hypochondrial pain, anorexia, asthenia, jaundice) which could occur after stopping treatment.

 

Source – MHRA

Class 4 Drug Alert: Crescent Pharma Ltd and Flamingo Pharma (UK) Ltd, Ibuprofen 400mg Tablets, (EL (20)A/10)

By | News, UK Pharma | No Comments

Crescent Pharma Ltd and Flamingo Pharma (UK) Ltd have informed us that the Patient Information Leaflet (PIL) within their packs for the above pharmacy (P) batches is incorrect.

Brief description of the problem

The PIL in the above batches includes incorrect dosing instructions in Section 3, How to take Ibuprofen.

The leaflet incorrectly states that ‘The maximum daily dose should not exceed 6 [six] tablets (2400 mg).’

This dosing regimen should only be given to patients who are under the supervision of their GP or healthcare prescriber and have been prescribed Ibuprofen 400mg Tablets. The outer carton contains the correct P indications and posology.

Crescent Pharma Ltd products

Ibuprofen 400mg Tablets (Almus Livery) PL 20416/0089

Batch Number Expiry Date Pack Size First Distributed
DO3210N 09.2022 84 11 Jun 19
DO3310N 09.2022 84 07 Aug 19
DO3410N 09.2022 84 11 Jun 19
DO3510N 09.2022 84 11 Jun 19
DO3610N 10.2022 84 18 Jul 19
DO3710N 10.2022 84 12 Mar 19
DO3811N 10.2022 84 12 Mar 19
DO3911N 10.2022 84 19 Jul 19

Ibuprofen 400mg Tablets (Crescent Livery) PL 20416/0089

Batch Number Expiry Date Pack Size First Distributed
001205M 04.2021 84 08 Aug 19
DO0101O 12.2022 84 10.Jan 20
DO0503O 02.2023 84 10 Jan 20

Flamingo Pharma (UK) Ltd products

Ibuprofen 400mg Tablets (Flamingo Pharma Livery) PL 43461/0005

Batch Number Expiry Date Pack Size First Distributed
1402177 Aug-23 24 Oct-18
1402268 Sep-23 48 Nov-18
1402278 Oct-23 24 Dec-18
1402308 Nov-23 84 Dec-18
1402309 Nov-23 84 Dec-18
1402310 Nov-23 84 Dec-18
1402316 Nov-23 84 Jan-19
1402317 Nov-23 84 Jan-19
1402318 Dec-23 24 Jan-19
1402337 Dec-23 48 Jan-19
1402338 Dec-23 48 Jan-19
1402363 Dec-23 48 Mar-19
1402353 Dec-23 48 Mar-19
1402354 Dec-23 48 Mar-19
1402352 Dec-23 84 Mar-19
1402361 Dec-23 84 Mar-19
1402362 Dec-23 84 Mar-19
1402368 Jan-24 48 Mar-19
1402369 Jan-24 24 Mar-19
1402370 Jan-24 24 Mar-19
1402424 Mar-24 24 Apr-19
1402425 Mar-23 48 Apr-19
1402543 May-24 48 Jul-19
1402544 May-24 48 Jul-19
1402554 Jun-24 24 Jul-19
1402557 Jun-24 84 Aug-19
1402558 Jun-24 48 Aug-19
1402559 Jun-24 48 Aug-19
1402622 Jul-24 48 Sep-19
1402623 Jul-24 48 Sep-19
1402624 Jul-24 24 Sep-19
1402625 Jul-24 24 Sep-19
1402628 Jul-24 24 Sep-19
1402670 Aug-24 24 Nov-19
1402671 Aug-24 24 Nov-19
1402672 Aug-24 24 Nov-19
1402673 Aug-24 24 Nov-19
1402674 Sep-24 48 Nov-19
1402686 Sep-24 48 Nov-19
1402687 Sep-24 48 Nov-19
1402688 Sep-24 48 Nov-19
1402705 Sep-24 48 Nov-19
1402706 Sep-24 84 Nov-19
1402707 Oct-24 48 Dec-19
1402708 Oct-24 48 Dec-19
1402709 Oct-24 84 Dec-19
1402710 Oct-24 84 Dec-19
1402711 Nov-24 84 Jan-20
1402837 Dec-24 24 Feb-20
1402838 Dec-24 24 Feb-20
1402854 Dec-24 48 Feb-20
1402839 Dec-24 96 Feb-20
1402852 Dec-24 96 Feb-20
1402853 Dec-24 84 Feb-20

Ibuprofen 400mg Tablets (TEVA Livery) PL 43461/0005

Batch Number Expiry Date Pack Size First Distributed
1402172 Jul-23 84 Sep-18
1402173 Jul-23 84 Sep-18
1402174 Aug-23 84 Oct-18
1402175 Aug-23 84 Oct-18
1402176 Aug-23 84 Oct-18
1402178 Aug-23 84 Oct-18
1402279 Nov-23 84 Dec-18

Advice for healthcare professionals

When dispensing or providing this product over the counter, please check the Marketing Authorisation Holder and the batch number; if any of the above batch numbers are being dispensed, ensure that patients are aware of the correct dosage instructions and maximum daily dose as stated on the carton labelling.

Correct statement: The maximum daily dose should not be more than 3 tablets (1200 mg).

Where possible, these packs should be considered to be dispensed against a prescription rather than sold over the counter to safeguard patients from taking a prescription only dose.

Class 2 Medicines recall: Ranitidine 150mg/10ml Oral Solution (EL (19)A/29)

By | News | No Comments

Rosemont Pharmaceuticals Limited is recalling unexpired stock from pharmacies as a precautionary measure due to possible contamination with an impurity.

Product information

PL number

PL 00427/0132

MDR Number

MDR 56-09/19

Company name

Rosemont Pharmaceuticals Limited (part of the Perrigo group)

Product description

Ranitidine 150mg/10ml Oral Solution (PL 00427/0132)

Brief description of the problem

Rosemont Pharmaceuticals Limited is recalling all unexpired stock of the above products from pharmacies as a precautionary measure due to possible contamination with an impurity N-nitrosodimethylamine (NDMA) which has genotoxic and carcinogenic potential.

Advice for healthcare professionals

  • Stop supplying the above products immediately. Quarantine all remaining stock and return it to your supplier using your supplier’s approved process.
  • If you receive queries about this issue from patients, advise them not to stop taking their medication as the health risk of discontinuing the medicine is higher than the potential risk presented by the contaminant. A treatment review is not necessary until the next routine appointment.

This is an on-going issue and the MHRA is actively involved with the European Medicines Agency and with other medicines regulators to determine any possible impact. An investigation into other potentially impacted products is continuing and further updates will be provided as the investigation progresses.

 

Source – MHRA

Class 2 Medicines recall: Sayana Press 104mg/0.65ml (MDR 055-06/19)

By | Other | No Comments

Pfizer Ltd is recalling certain batches of Sayana Press for subcutaneous injection.

Product information

PL number

PL 00057 / 1093

MDR Number

MDR 055-06/19

Company name

Pfizer Limited

Product description

Sayana Press 104mg/0.65ml, medroxyprogesterone acetate suspension for injection (PL 00057 / 1093)

Batch Number Expiry Date Pack Size First Distributed
L61367 31 January 2020 1 10 April 2015
L61367Y 31 January 2020 1 02 May 2016
T34580 31 July 2020 1 08 November 2017
X49124 30 June 2021 1 09 October 2018

Brief description of the problem

Pfizer Ltd has informed us of an issue related to the sealing process for some units of Sayana Press for subcutaneous (SC) injection potentially impacting the above listed batches. Sayana Press for subcutaneous (SC) injection is provided in a single-dose Uniject pre-filled injection system. During routine re-inspection of unreleased product batches, two related defects were observed;

  • injectors with moisture outside the sealed area with a wet label, immediately after their removal from the pouch
  • injectors with a temporarily unreadable expiry date on the unit label

The root cause analysis shows that the leak was attributed to a failure in the sealing process of the injection system and may impact the integrity of the product. Pfizer’s health assessment of the issue concluded that the use of the impacted product has an unlikely probability of being associated with adverse events and the potential risk to patients is considered to be negligible.

 

Source ~ MHRA

Class 2 Medicines recall: Zantac Injection 50mg/2ml, Zantac Syrup 150mg/10ml, Zantac Tablets 150mg, Zantac Tablets 300mg (EL (19)A 24)

By | News, UK Pharma | No Comments

GlaxoSmithKline, trading as Glaxo Welcome Ltd, is recalling all unexpired stock of Zantac (ranitidine hydrochloride) prescription only medicines (POM) from pharmacies.

Source – MHRA

Class 4 Medicines Defect Information: Prednisolone 5mg Tablets (MDR 61-04/19)

By | News | No Comments

Genesis Pharmaceuticals Ltd has informed us that there is an error on the Braille for the above batches which means that the strength reads as 1mg instead of 5mg. The printed text is correct on all packaging.

Product description
Prednisolone 5mg Tablets. PL 42967/0037.

Batch Number Expiry Date Pack Size First Distributed
1809653 08/2021 1 x 28 28/01/2019
1809654 08/2021 1 x 28 28/01/2019
1809655 08/2021 1 x 28 30/01/2019
1809656 08/2021 1 x 28 06/02/2019
1809657 08/2021 1 x 28 26/02/2019

Advice for healthcare professionals
There is a risk to patients who have compromised eye-sight and who rely solely on Braille to determine their tablet strength.

Packs from the above distributor with the above batch numbers should not be dispensed to patients who rely solely on Braille.

We understand that alternative batches of the product are available from a number of suppliers.

Further information
For further information, please contact Genesis Pharmaceuticals Ltd, on 020 7201 0400.

Recipients of this Drug Alert should bring it to the attention of relevant contacts by copy of this letter. NHS regional teams are asked to forward this to community pharmacists and dispensing general practitioners for information.

Ativan 4mg/1ml Solution for injection CLASS 4 MEDICINES DEFECT INFORMATION

By | News | No Comments

CLASS 4 MEDICINES DEFECT INFORMATION – Ativan 4mg/1ml Solution for injection

Dear Healthcare Professional, Pfizer Limited Ativan 4mg/1ml Solution for injection PL 00057/1279 (Lorazepam)

Batch Number Expiry Date Pack Size First Distributed

4091 Oct 2019 10 x 1ml 15 Apr 2019

4092 Dec 2019 10 x 1ml 10 Apr 2019

4094 Dec 2019 10 x 1ml NA

Pfizer Limited has informed us that the text on the carton label for the above product has recently been updated and at this time, the product description on the carton was changed from 10 x 1ml ampoules to 10 x 2ml ampoules. The updated text reflects the size of the ampoules, which is 2ml. The concentration and total volume of the ampoules has not changed and remains 4mg Lorazepam in 1ml of solution.
The size of the ampoules (2ml) has not changed and the label on the ampoules remains unchanged and states ‘4mg in 1ml’.

We understand that the carton label is in the process of being revised to reflect the volume of solution contained in the ampoules and batches with the revised labels are expected to become available during Q3 2019.
Further Information

Class 2 Medicines Recall: Actavis Group PTC EHF – recall of batches of Irbesartan/Hydrochlorothiazide 300/12.5mg Film-coated Tablets and Irbesartan/Hydrochlorothiazide 150/12.5mg Film-coated Tablets

By | News | No Comments

Actavis Group PTC EHF is recalling the below batches from pharmacies as a precautionary measure due to possible contamination with N‑nitrosodiethylamine (NDEA).

Actavis Group PTC EHF

Irbesartan/Hydrochlorothiazide 300/12.5mg Film-coated Tablets, PL 30306/0266

Batch number Expiry date Pack size Date of first distribution
059118 31/03/2020 1 x 28 17/09/2018
099218 31/03/2020 1 x 28 04/10/2018
191418 31/05/2020 1 x 28 25/10/2018

Irbesartan / Hydrochlorothiazide 150/12.5mg Film-coated Tablets, PL 30306/0265

Batch number Expiry date Pack size Date of first distribution
150118 30/04/2020 1 x 7 12/09/2018

Healthcare Professionals and wholesalers

  • Stop supplying the above batches listed above immediately. Quarantine all remaining stock and return it to your supplier using your supplier’s approved process.
  • If you receive queries about this issue from patients, advise them not to stop taking their medication as the health risk of discontinuing the medicine is higher than the potential risk presented by the contaminant. A treatment review is not necessary until the next routine appointment.
  • We do not anticipate any shortages of Irbesartan containing products. It is possible, however, that there may be some local supply issues, in which case patients should be advised to speak to their doctor to discuss alternative treatments.

This is a developing issue and the MHRA is actively involved with the European Medicines Agency and with other medicines regulators to determine any possible impact. An investigation into other potentially impacted products is continuing and further updates will be provided as the investigation progresses.

(SOURCE – MHRA)

Class 2 Medicines Recall: Teva UK Limited and Mylan – recall of some Valsartan containing products

By | Other | No Comments

Some valsartan containing products including certain batches supplied by Teva UK Limited and all unexpired batches supplied by Mylan are being recalled.

Class 2 Medicines Recall: Teva UK Limited and Mylan – recall of some Valsartan containing products – GOV.UK

Company name

Teva UK Limited

Valsartan 320mg Film-coated Tablets, PL 00289/1238

BATCH NUMBER EXPIRY DATE PACK SIZE DATE OF FIRST DISTRIBUTION
100433 28/02/2019 1 x 28 21/06/2017
101777 31/07/2019 1 x 28 15/01/2018

Valsartan 40mg Film-coated Tablets, PL 00289/1235

BATCH NUMBER EXPIRY DATE PACK SIZE DATE OF FIRST DISTRIBUTION
100350 28/02/2019 1 x 7 01/06/2017
100938 30/04/2019 1 x 7 03/01/2018
101776 31/08/2019 1 x 7 13/09/2018

Valsartan / Hydrochlorothiazide 80 / 12.5mg Film-coated Tablets, PL 00289/1233

BATCH NUMBER EXPIRY DATE PACK SIZE DATE OF FIRST DISTRIBUTION
6P601163 31/01/2019 1 x 28 23/06/2016
6P606333 30/06/2019 1 x 28 07/10/2016
0001584 31/12/2019 1 x 28 26/04/2017
0002626 31/03/2020 1 x 28 25/08/2017
0002627 31/03/2020 1 x 28 05/07/2017
0003214 30/04/2020 1 x 28 30/10/2017
0004744 31/08/2020 1 x 28 27/12/2017

Valsartan / Hydrochlorothiazide 160 / 12.5mg Film-coated Tablets, PL 00289/1215

BATCH NUMBER EXPIRY DATE PACK SIZE DATE OF FIRST DISTRIBUTION
6P607166 31/07/2019 1 x 28 07/10/2016
0000426 30/09/2019 1 x 28 13/02/2017
0001520 31/12/2019 1 x 28 04/05/2017
0001521 31/12/2019 1 x 28 25/05/2017
0002298 29/02/2020 1 x 28 16/08/2017
0003663 31/05/2020 1 x 28 27/09/2017
0004670 31/08/2020 1 x 28 11/12/2017

Valsartan / Hydrochlorothiazide 160 / 25mg Film-coated Tablets, PL 00289/1234

BATCH NUMBER EXPIRY DATE PACK SIZE DATE OF FIRST DISTRIBUTION
6P601084 31/01/2019 1 x 28 19/05/2016
6P606270 30/06/2019 1 x 28 13/09/2016
0000350 30/09/2019 1 x 28 23/01/2017
0000352 30/09/2019 1 x 28 12/04/2017
0001997 31/01/2020 1 x 28 12/06/2017
0002338 29/02/2020 1 x 28 16/08/2017
0003615 31/05/2020 1 x 28 27/09/2017

Mylan

MEDLINE PRODUCT PL NUMBER
Valsartan 40mg Capsules PL 04569/1000
Valsartan 80mg Capsules PL 04569/1001
Valsartan 160mg Capsules PL 04569/1002
Valsartan 40mg Film-coated Tablets PL 04569/1175
Valsartan 320mg Film-coated Tablets PL 04569/1178

Further to Drug Alert number EL (18) A/11, issued in July 2018 in connection with Valsartan containing products contaminated with N-nitrosodimethylamine (NDMA), we have become aware of another nitrosamine contaminant in batches of Valsartan active substance.

This contaminant is N‑nitrosodiethylamine (NDEA), which also has genotoxic and carcinogenic potential. Valsartan containing products from UK suppliers Teva UK Limited and Mylan are affected.

Teva is recalling the listed batches and Mylan is recalling all unexpired batches of the above products from pharmacies as a precautionary measure at a European level due to possible contamination with NDEA.

Healthcare Professionals and wholesalers

  • Stop supplying the above products / batches listed above immediately. Quarantine all remaining stock and return it to your supplier using your supplier’s approved process.
  • If you receive queries about this issue from patients, advise them not to stop taking their medication as the health risk of discontinuing the medicine is higher than the potential risk presented by the contaminant. A treatment review is not necessary until the next routine appointment.
  • We do not anticipate any shortages of Valsartan containing products. It is possible, however, that there may be some local supply issues, in which case patients should be advised to speak to their doctor to discuss alternative treatments.

This is a developing issue and the MHRA is actively involved with the European Medicines Agency and with other medicines regulators to determine any possible impact. An investigation into other potentially impacted products is continuing and further updates will be provided as the investigation progresses.

Company contacts for further information

Teva UK Limited

For stock control:general.enquiries@tevauk.com

For medical information enquiries: medinfo@tevauk.com

Mylan

For stock control: mguk_customer.services@mylan.co.uk, 01707 853100

For medical information enquiries:info@mylan.co.uk, 01707 853 000, Option 1

Recipients of this Drug Alert should bring it to the attention of relevant contacts by copy of this letter. Local area teams are asked to forward this to relevant clinics, general practitioners and community pharmacists.